Komori
Presentation materials for financial results4523Eisai Co.,Ltd.Pharmaceuticals

Reference Materials for the Full-Year Results for FY2025 (Fiscal Year Ending March 2026)

In FY2025, revenue increased by ¥36.0 billion, while operating profit decreased by ¥10.2 billion and profit attributable to owners of the parent decreased by ¥7.9 billion. For FY2026, the Company forecasts revenue of ¥883.5 billion, operating profit of ¥70.0 billion and profit attributable to owners of the parent of ¥52.3 billion.

Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-102
¥100 million (year-on-year change in operating profit)
Wording
Conditional
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFY2025 (fiscal year ending March 2026), full year11 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales8,254 Hundreds of millions of yen+4.6%
Operating profit441 Hundreds of millions of yen-18.8%
Ordinary income510 Hundreds of millions of yen-16.5%
Net income¥386 100 million -17.0%attributable to owners of the parent
Selling, general and administrative expenses4,353 Hundreds of millions of yen
Gross Profit Margin
Rate76.8%
Year-on-year change (points)Down 1.8 percentage points from 78.6% in the same period of the previous fiscal year
Operating profit margin
Rate5.3%
Year-on-year change (points)Down 1.6 percentage points from 6.9% in the same period of the previous fiscal year
Results for the three months of the current quarterFourth quarter of FY2025: revenue of ¥205.4 billion, operating loss of ¥10.3 billion and quarterly loss attributable to owners of the parent of ¥3.2 billion
Full-year earnings forecast
Revenue
8,835 Hundreds of millions of yen
Operating profit
700 Hundreds of millions of yen
Profit before tax
740 Hundreds of millions of yen
Profit attributable to owners of the parent
523 Hundreds of millions of yen
Profit for the period
540 Hundreds of millions of yen
EPS
¥185
DPS
¥160
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Increase in costs of sales-224 Hundreds of millions of yen
  • Increase in selling, general and administrative expenses-273 Hundreds of millions of yen
  • Decrease in R&D Expenses130 Hundreds of millions of yen
  • Decrease in other income-119 Hundreds of millions of yen
  • Decrease in other expenses24 Hundreds of millions of yen
  • Impact of foreign exchange movements on operating profit55.5 Hundreds of millions of yen
  • Decrease in one-time payments and other items related to the transfer of rights (core operating profit adjustment)346 Hundreds of millions of yen
  • Gains and losses on the sale of property, plant and equipment-28 Hundreds of millions of yen
  • Increase in termination benefit expenses associated with business restructuring-48 Hundreds of millions of yen
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
  • USD/JPY153
  • Euro/Japanese yen180
  • Pound sterling/Japanese yen205
  • Chinese yuan/Japanese yen22.5
New initiatives
  • U.S. approval and launch of maintenance therapy using the Leqembi subcutaneous autoinjector (SC-AI)
  • Applications in Japan, China and the United States for initial therapy using Leqembi SC-AI
  • Acquisition of rights related to serplulimab and taletrectinib
  • Structural reform in Europe
Key KPIsA metric the company considers important as a management benchmark.
  • Leqembi revenue880 Hundreds of millions of yen
    Year on year against the same period last year+98.7%
  • Dayvigo revenue643 Hundreds of millions of yen
    Year on year against the same period last year+19.6%
  • Revenue from products in the neurology area2,606 Hundreds of millions of yen
    Year on year against the same period last year+30.4%
  • Revenue from products in the oncology area3,627 Hundreds of millions of yen
    Year on year against the same period last year-0.9%
  • Overseas revenue ratio71.3 %
    Year on year against the same period last year+0.3%
Segment results
Pharmaceuticals total
Revenue
8,108 Hundreds of millions of yen+8.2%
Segment profit
3,673 Hundreds of millions of yen+4.8%
Japan
Revenue
2,292 Hundreds of millions of yen+6.0%
Segment profit
730 Hundreds of millions of yen+1.8%
Americas
Revenue
3,004 Hundreds of millions of yen+8.0%
Segment profit
1,744 Hundreds of millions of yen+10.2%
China
Revenue
1,307 Hundreds of millions of yen+13.2%
Segment profit
593 Hundreds of millions of yen+3.7%
EMEA
Revenue
815 Hundreds of millions of yen+2.7%
Segment profit
304 Hundreds of millions of yen-15.4%
East Asia and Global South
Revenue
688 Hundreds of millions of yen+15.6%
Segment profit
302 Hundreds of millions of yen+10.5%
Other Businesses
Revenue
146 Hundreds of millions of yen-63.8%
Segment profit
45 Hundreds of millions of yen-84.8%
Financial targets
Adjusted ROIC
FY2025 actual6.8%
FY2026 forecast8.7%
ROE
FY2025 actual4.4%
FY2026 forecast5.9%
Number of employees
Number of Employees10,543 people consolidated, as of 31 March 2026
Change during the periodDown 524 from 11,067 in the same period of the previous fiscal year
Capital expenditures
¥412 100 million FY2025 capital expenditures, cash basis
Annual Dividend
Annual dividend per share¥160
Payout ratio
117.0%
Acquisition of treasury shares
Expenditure on acquisitions in FY20250 Hundreds of millions of yen
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredFY2025 (fiscal year ending March 2026), full year
Net Sales8,254 Hundreds of millions of yen (YoY +4.6%)
Operating profit441 Hundreds of millions of yen (YoY -18.8%)
Ordinary income510 Hundreds of millions of yen (YoY -16.5%)
Net income¥386 100 million (attributable to owners of the parent) (YoY -17.0%)
Gross Profit MarginRate 76.8% / Year-on-year change (points) Down 1.8 percentage points from 78.6% in the same period of the previous fiscal year
Operating profit marginRate 5.3% / Year-on-year change (points) Down 1.6 percentage points from 6.9% in the same period of the previous fiscal year
Selling, general and administrative expenses4,353 Hundreds of millions of yen
Results for the three months of the current quarterFourth quarter of FY2025: revenue of ¥205.4 billion, operating loss of ¥10.3 billion and quarterly loss attributable to owners of the parent of ¥3.2 billion
Full-year earnings forecastRevenue 8,835 Hundreds of millions of yen / Operating profit 700 Hundreds of millions of yen / Profit before tax 740 Hundreds of millions of yen / Profit attributable to owners of the parent 523 Hundreds of millions of yen / Profit for the period 540 Hundreds of millions of yen / EPS ¥185 / DPS ¥160
Segment resultsPharmaceuticals total Revenue 8,108 Hundreds of millions of yen (YoY +8.2%) / Segment profit 3,673 Hundreds of millions of yen (YoY +4.8%) / Japan Revenue 2,292 Hundreds of millions of yen (YoY +6.0%) / Segment profit 730 Hundreds of millions of yen (YoY +1.8%) / Americas Revenue 3,004 Hundreds of millions of yen (YoY +8.0%) / Segment profit 1,744 Hundreds of millions of yen (YoY +10.2%) / China Revenue 1,307 Hundreds of millions of yen (YoY +13.2%) / Segment profit 593 Hundreds of millions of yen (YoY +3.7%) / EMEA Revenue 815 Hundreds of millions of yen (YoY +2.7%) / Segment profit 304 Hundreds of millions of yen (YoY -15.4%) / East Asia and Global South Revenue 688 Hundreds of millions of yen (YoY +15.6%) / Segment profit 302 Hundreds of millions of yen (YoY +10.5%) / Other Businesses Revenue 146 Hundreds of millions of yen (YoY -63.8%) / Segment profit 45 Hundreds of millions of yen (YoY -84.8%)
Breakdown of Factors Affecting the ChangeFactors Increase in costs of sales / Amount -224 Hundreds of millions of yen, Factors Increase in selling, general and administrative expenses / Amount -273 Hundreds of millions of yen, Factors Decrease in R&D Expenses / Amount 130 Hundreds of millions of yen, Factors Decrease in other income / Amount -119 Hundreds of millions of yen, Factors Decrease in other expenses / Amount 24 Hundreds of millions of yen, Factors Impact of foreign exchange movements on operating profit / Amount 55.5 Hundreds of millions of yen, Factors Decrease in one-time payments and other items related to the transfer of rights (core operating profit adjustment) / Amount 346 Hundreds of millions of yen, Factors Gains and losses on the sale of property, plant and equipment / Amount -28 Hundreds of millions of yen, Factors Increase in termination benefit expenses associated with business restructuring / Amount -48 Hundreds of millions of yen
Key KPIsIndicator name Leqembi revenue / Value 880 Hundreds of millions of yen / Year on year against the same period last year 98.7 Hundreds of millions of yen, Indicator name Dayvigo revenue / Value 643 Hundreds of millions of yen / Year on year against the same period last year 19.6 Hundreds of millions of yen, Indicator name Revenue from products in the neurology area / Value 2,606 Hundreds of millions of yen / Year on year against the same period last year 30.4 Hundreds of millions of yen, Indicator name Revenue from products in the oncology area / Value 3,627 Hundreds of millions of yen / Year on year against the same period last year -0.9 Hundreds of millions of yen, Indicator name Overseas revenue ratio / Value 71.3 % / Year on year against the same period last year 0.3 %
Number of employeesNumber of Employees 10,543 people (consolidated, as of 31 March 2026) / Change during the period Down 524 from 11,067 in the same period of the previous fiscal year
Assumptions Underlying the Business OutlookItem USD/JPY / Value 153, Item Euro/Japanese yen / Value 180, Item Pound sterling/Japanese yen / Value 205, Item Chinese yuan/Japanese yen / Value 22.5
Financial targetsAdjusted ROIC FY2025 actual 6.8% / FY2026 forecast 8.7% / ROE FY2025 actual 4.4% / FY2026 forecast 5.9%
Annual DividendAnnual dividend per share ¥160 / Breakdown Not disclosed
Payout ratio117.0%
Acquisition of treasury sharesExpenditure on acquisitions in FY2025 0 Hundreds of millions of yen / Buyback limit Not disclosed / Period Not disclosed
Capital expenditures¥412 100 million (FY2025 capital expenditures, cash basis)
New initiativesU.S. approval and launch of maintenance therapy using the Leqembi subcutaneous autoinjector (SC-AI), Applications in Japan, China and the United States for initial therapy using Leqembi SC-AI, Acquisition of rights related to serplulimab and taletrectinib, Structural reform in Europe
Items this document does not state (9)
Progress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue increased on growth in Leqembi, Lenvima and Dayvigo, while one-time items, including ¥15.1 billion in proceeds from the transfer of product rights recorded in the previous fiscal year, declined substantially in the current fiscal year. Operating profit was affected by higher selling, general and administrative expenses, including investment in Leqembi, restructuring costs in Europe and an increase in the shared profits from Lenvima, as well as by the decline in one-time gains recorded in the previous fiscal year. The materials also disclose a ¥5.55 billion increase in operating profit from lower research and development expenses and foreign exchange movements.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Reference Materials for the Full-Year Results for FY2025 (Fiscal Year Ending March 2026) | Eisai Co.,Ltd. (4523) timely disclosure | Komori